The Trump trade comes unstuck

Bullish investors may wish to consider a safer way to play the Trump trade than Wall Street,s ays Andrew Van Sickle.

Last September, Donald Trump dismissed the buoyant US stockmarket as a "fat bubble", says Randall W. Forsyth in Barron's. But last week he was quite happy to take credit for the Dow Jones index's move past 20,000, an event that has been feverishly anticipated for months. Rarely has such a fuss been made about something so trivial, as John Authers points out in the Financial Times. "No sentient and sensible human being should base any investment decision on the Dow. Its methodological flaws are irremediable."

The problem is that a company's weighting in the index is based on its share price, rather than its market capitalisation (price multiplied by the number of shares in issue), which is the case with most indices. So a firm with a high share price is automatically more important in the Dow than a bigger and more important one that has more shares available, yet just happens to have a lower stock price.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Andrew Van Sickle
Editor, MoneyWeek

Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.

After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.

His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.

Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.